NaviFUS (ROCO:6872) Debt-to-Asset : 0.04 (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Debt-to-Asset?

NaviFUS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was NT$7.39 Mil. NaviFUS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was NT$18.31 Mil. NaviFUS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was NT$735.24 Mil. NaviFUS's debt to asset for the quarter that ended in Mar. 2025 was 0.03.

NaviFUS Debt-to-Asset Historical Data

The historical data trend for NaviFUS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Debt-to-Asset Chart

NaviFUS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.07

0.05

NaviFUS Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial											0.05	0.05	0.05	0.05	0.04

Competitive Comparison of NaviFUS's Debt-to-Asset

For the Biotechnology subindustry, NaviFUS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NaviFUS's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NaviFUS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NaviFUS's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

NaviFUS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NaviFUS's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.354	+	20.174)	/	546.687
	=	0.05

NaviFUS's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.388	+	18.314)	/	735.239
	=	0.03

NaviFUS (ROCO:6872) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NaviFUS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NaviFUS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NaviFUS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 508, Section 7 , Zhongxiao East Road, 16th Floor, Nangang District, Taipei City, TWN, 103

Website

https://www.navifus.com

NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS Headlines

No Headlines